KRT18P16

Across TCGA pan-cancer cohorts, KRT18P16 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated KRT18P16 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher KRT18P16 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated KRT18P16 expression acts as an unfavorable survival marker, although some lineages such as THCA and BLCA show a favorable association.

LUAD, CHOL, and PAAD are the cancer types where KRT18P16 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.744	0.831	.002	34	view →
CHOL	OS	Median	III,IV	0.286	1.000	.008	29	view →
PAAD	OS	Quartile	All	0.240	0.598	.003	27	view →
THCA	OS	Quartile	All	1.000	0.894	.005	20	view →
LAML	DFS	Quartile	All	0.443	0.676	.010	18	view →
ACC	DFS	Tertile	II,III,IV	0.191	0.502	.011	18	view →
ESCA	OS	Median	All	0.647	1.000	.015	15	view →
SARC	DFS	Tertile	All	0.339	0.530	.021	15	view →
STAD	DFS	Quartile	III,IV	0.236	0.624	.003	13	view →
KIRC	DFS	Quartile	All	0.767	0.837	.017	13	view →
BLCA	DFS	Tertile	IV	0.577	0.318	.032	12	view →
DLBC	OS	Tertile	All	0.206	0.942	.005	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

KRT18P16–LUAD (DFS)

Open the LUAD breakdown →